Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields
<b>Background:</b> Modern viral vector production needs to consider process intensification for higher yields from smaller production volumes. However, innate antiviral immunity triggered in the producer cell may limit virus replication. While commonly used cell lines (e.g., Vero or E1A-immortalised cells) are already compromised in antiviral pathways, the redundancy of innate signaling complicates host cell optimization by genetic engineering. Small molecules that are hypothesized to target antiviral pathways (Viral Sensitizers, VSEs) added to the culture media offer a versatile alternative to genetic modifications to increase permissiveness and, thus, viral yields across multiple cell lines. <b>Methods:</b> To explore how the yield for a chimeric Zika vaccine candidate (YF-ZIK) could be further be increased in an intensified bioprocess, we used spin tubes or an Ambr15 high-throughput microbioreactor system as scale-down models to optimize the dosing for eight VSEs in three host cell lines (AGE1.CR.pIX, BHK-21, and HEK293-F) based on their tolerability. <b>Results:</b> Addition of VSEs to an already optimized infection process significantly increased infectious titers by up to sevenfold for all three cell lines tested. The development of multi-component VSE formulations using a design of experiments approach allowed further synergistic titer increases in AGE1.CR.pIX cells. Scale-up to 1 L stirred-tank bioreactors and 3D-printed mimics of 200 or 2000 L reactors resulted in up to threefold and eightfold increases, respectively. <b>Conclusions:</b> Addition of single VSEs or combinations thereof allowed a further increase in YF-ZIK titers beyond the yield of an already optimized, highly intensified process. The described approach validates the use of VSEs and can be instructive for optimizing other virus production processes.
Authors
- Jean‐Simon Diallo (ORCID: https://orcid.org/0000-0002-4862-2795)
- Volker Sandig (ORCID: https://orcid.org/0000-0003-3889-2078)
- A. Vervoort
- Peter Satzer (ORCID: https://orcid.org/0000-0003-3907-4755)
- Ingo Jordan (ORCID: https://orcid.org/0000-0003-2711-7252)
- Jondavid de Jong
- Udo Reichl (ORCID: https://orcid.org/0000-0001-6538-1332)
- Yvonne Genzel (ORCID: https://orcid.org/0000-0002-2652-5943)
- Kai Dallmeier (ORCID: https://orcid.org/0000-0002-8117-9166)
- Sven Göbel (ORCID: https://orcid.org/0000-0002-2264-5569)
- Tilia Zinnecker (ORCID: https://orcid.org/0009-0008-9514-3069)
- Manfred Satzer
Institutions
- Beiersdorf (Germany) (DE)
- University of Ottawa (CA)
- Rega Institute for Medical Research (BE)
- Ottawa Hospital (CA)
- Vancouver Biotech (Canada) (CA)
- Max Planck Institute for Dynamics of Complex Technical Systems (DE)
- Ottawa Hospital Research Institute (CA)
- Otto-von-Guericke-Universität Magdeburg (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Vaccines
- Published
- 2025-07-16
- DOI
- https://doi.org/10.3390/vaccines13070757
- Citations
- 1
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology